Polimorfismo C677T do gene mthfr na susceptibilidade à hipertensão arterial: evidências baseadas em metanálise / C677T polymorphism of the mthfr gene in susceptibility to arterial hypertension: evidences based on meta-analysis

Raphaela Gomes de Oliveira, Elisângela Gomes da Silva, Lucas Cândido Gonçalves, Jacqueline Andréia Bernardes Leão-Cordeiro, Fábio Silvestre Ataídes, Antonio da Silva Menezes Junior, Paulo Alex Neves da Silva, Lilian Carla Carneiro, Xisto Sena Passos, Antonio Márcio Teodoro Cordeiro Silva

Abstract


Introdução: A hipertensão arterial sistêmica (HAS) é uma doença multifatorial, e, dentre os fatores destaca-se a genética, com ênfase ao polimorfismo C677T do gene mthfr, que após codificado, regula o metabolismo da homocisteína, substância danosa aos vasos sanguíneos quando em alta concentração. Objetivo: Avaliar a associação do polimorfismo C677T do gene mthfr e a hipertensão arterial sistêmica. Métodos: Trata-se de revisão sistemática com metanálise, com busca nas bases de dados: PubMed e SciELO, de acordo com os critérios de elegibilidade. Os dados de 20 artigos foram extraídos e os testes estatísticos, considerando limite de significância igual a 5%, foram realizados com o auxílio do software RevMan® 5.4. Resultados: A avaliação genotípica do polimorfismo C677T do gene mthfr apontou relação entre os genótipos TT (mutante) e CT (heterozigoto) com a HAS (respectivamente, OR=1,21; IC95%=1,03-1,43 e OR=1,52; IC95%=1,19-1,95). Na avaliação alélica, a associação ocorreu com o alelo T (OR=1,33; IC95%=1,17-1,53). Os resultados sugerem que o genótipo CC (selvagem) e o alelo C conferem proteção contra a HAS (CC: OR=0,66; IC95%=0,54-0,81 e C: OR=0,82; IC95%=0,74-0,90). Conclusão: Existe associação entre o polimorfismo C677T do gene mthfr e a hipertensão arterial sistêmica. A presença do alelo T em homozigose ou heterozigose aumenta a suscetibilidade genética individual para o desenvolvimento da HAS.

 


Keywords


Hipertensão; Polimorfismo de Nucleotídeo Único; Biologia Molecular; Metanálise.

References


McMahon A, McNulty H, Hughes CF, Strain JJ, Ward M. Novel approaches to investigate one-carbon metabolism and related B-vitamins in blood pressure. Nutrients. 2016;8(11):1–20.

World Health Organization. Global Status Report on noncommunicable diseases. Genebra. 2011.

LI Y-Y, TANG K-T, MEN C, YANG K-M, ZHAN Y-Y, JIA J, et al. Methylenetetrahydrofolate reductase C677T gene polymorphism and essential hypertension: A meta-analysis of 10,415 subjects. Biomed Reports. 2014;2(5):699–708.

Nassereddine S, Kassogue Y, Korchi F, Habbal R, Nadifi S. Association of methylenetetrahydrofolate reductase gene (C677T) with the risk of hypertension in Morocco. BMC Res Notes. 2015;8(1):1–5.

Fan S, Yang B, Zhi X, Wang Y, Wei J, Zheng Q, et al. Interactions of methylenetetrahydrofolate reductase C677T polymorphism with environmental factors on hypertension susceptibility. Int J Environ Res Public Health. 2016;13(6):1–13.

Liu S, Liu M, Li Q, Liu X, Wang Y, Mambiya M, et al. Association of single nucleotide polymorphisms of MTHFR , TCN2 , RNF213 with susceptibility to hypertension and blood pressure. Biosci Rep. 2019;39(s/n):1–11.

Ferreira LB, Rola MG. Polimorfismos genéticos associados à hipertensão arterial sistêmica. Univ Ciências da Saúde. 2008;6(1):57–68.

Cheng J, Tao F, Liu Y, Venners SA, Hsu YH, Jiang S, et al. Associations of methylenetetrahydrofolate reductase C677T genotype with blood pressure levels in Chinese population with essential hypertension. Clin Exp Hypertens. 2018;40(3):207–12.

Vannucchi H, Melo SS. Hiper-homocisteinemia e risco cardiometabólico. Arq Bras Endocrinol Metabol. 2009;53(5):540–9.

McAuley E, McNulty H, Hughes C, Strain JJ, Ward M. Riboflavin status, MTHFR genotype and blood pressure: Current evidence and implications for personalised nutrition. Proc Nutr Soc. 2016;75(3):405–14.

Lopes LBN; DMM; AC. Artigo de revisão. J Bras Patol Med Lab. 2004;40(5):311–20.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10(1):111–3.

Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A Second Genetic Polymorphism in Methylenetetrahydrofolate Reductase ( MTHFR ) Associated with Decreased Enzyme Activity. Mol Genet Metab. 1998;172:169–72.

Yang N, Li L, Zhong J, Rodrı AC. Methylenetetrahydrofolate Reductase Gene Polymorphism and Risk of Type 2 Diabetes Mellitus. 2013;8(9).

Marinho C, Alho I, Arduíno D, Falcão LM, Brás-Nogueira J, Bicho M. GST M1/T1 and MTHFR polymorphisms as risk factors for hypertension. Biochem Biophys Res Commun. 2007;353(2):344–50.

Lwin H, Yokoyama T, Yoshiike N, Saito K, Yamamoto A, Date C, et al. Polymorphism of Methylenetetrahydrofolate Reductase Gene ( C677T MTHFR ) is Not a Confounding Factor of. Circ J. 2006;70(January):83–7.

Markan S, Sachdeva M, Sehrawat BS, Kumari S, Jain S, Khullar M. MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians. Mol Cell Biochem. 2007;302(1–2):125–31.

Sousa MR de, Ribeiro ALP. Revisão sistemática e meta-análise de estudos de diagnóstico e prognóstico: um tutorial. Arq Bras Cardiol. 2009;92(3):241–51.

Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic Reviews and Meta-Analyses : The PRISMA Statement. 2009;6(7).

Silva CN da, Silva DN da, Moraes KL, Cordeiro JABL, Brasil VV, Saddi VA, et al. GSTM1 and GSTT1 genes null polymorphisms in kidney cancer susceptibility: evidence based on a meta-analysis. J Bras Nefrol. 2015;37(2):248–54.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. 2002;1558(s/n):1539–58.

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

Juárez-Velázquez R, Canto P, Canto-Cetina T, Rangel-Villalobos H, Rosas-Vargas H, Rodríguez M, et al. Analysis of polymorphisms in genes (AGT, MTHFR, GPIIIa, and GSTP1) associated with hypertension, thrombophilia and oxidative stress in Mestizo and Amerindian populations of México. Dis Markers. 2010;28(5):323–31.

Gašparovi J, Rašlová K, Bašistová Z, Zacharová M, Wsólová L, Ová MAČ, et al. Effect of C677T Methylenetetrahydrofolate Reductase Gene Polymorphism on Plasma Homocysteine Levels in Ethnic Groups. Physiol Res. 2004;53(2):215–8.

Nefic H, MackicDjurovic M, Eminovic I. The Frequency of the 677C>T and 1298A>C Polymorphisms in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in the Population. Med Arch. 2018;72(3):164–9.

Edelweiss F. Tavares JPBV-F, Adagmar Andriolo ABAP, Sañudo NVA, Suely G. A. Gimeno LJF. Serum Total Homocysteine Levels and the Prevalence of Folic Acid Deficiency and C677T Mutation at the MTHFR Gene in an Indigenous Population of Amazonia: The Relationship of Homocysteine With Other Cardiovascular Risk Factors. Ethn Dis. 2004;14(3):50–6.

Herkenhoff ME, Guilherme Backes R, Gaulke R, Rosália Remualdo V. Frequência genotípica em amostras de MTHFR para o polimorfismo C677T em pacientes da cidade de Curitiba-PR Genotype frequency in MTHFR samples to C677T polimorphism in patients from the city of Curitiba-PR. Bras Patol Med Lab. 2012;48:435–8.

Kucuksu M, Ilhan N, Kaman D, Ozbay Y, Ilhan N. The 677 C/T MTHFR Polymorphism is Associated with Essential Hypertension, Coronary Artery Disease, and Higher Homocysteine Levels. Arch Med Res. 2007;39(1):125–30.

CAI W, YANG F, YIN L, ZHANG L, CHENG J. Association between Hcy levels and the CBS844ins68 and MTHFR C677T polymorphisms with essential hypertension. Biomed Reports. 2014;2(6):861–8.

Yang B, Fan S, Zhi X, Li Y, Liu Y, Wang D, et al. Associations of MTHFR gene polymorphisms with hypertension and hypertension in pregnancy: A meta-analysis from 114 studies with 15411 cases and 21970 controls. PLoS One. 2014;9(2):1–13.

Qian X, Lu Z, Tan M, Liu H, Lu D. A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension. Eur J Hum Genet. 2007;15(12):1239–45.

Alghasham A, Settin AA, Ali A. Association of MTHFR C677T and A1298C Gene Polymorphisms with Hypertension. Int J Health Sci (Qassim). 2014;6(1):3–11.

Bayramoglu A, Urhan Kucuk M, Guler HI, Abaci O, Kucukkaya Y, Colak E. Is there any genetic predisposition of MMP-9 gene C1562T and MTHFR gene C677T polymorphisms with essential hypertension? Cytotechnology. 2013;67(1):115–22.

Lin PT, Cheng CH, Wei JCC, Huang YC. Low plasma pyridoxal 5′-phosphate concentration and MTHFR 677C → T genotypes are associated with increased risk of hypertension. Int J Vitam Nutr Res. 2008;78(1):33–40.

Fowdar JY, Lason M V., Szvetko AL, Lea RA, Griffiths LR. Investigation of homocysteine-pathway-related variants in essential hypertension. Int J Hypertens. 2012;2012:1–9.

Tylicki L, Födinger M, Puttinger H, Rutkowski P, Strozecki P, Tyszko S, et al. Methylenetetrahydrofolate reductase gene polymorphisms in essential hypertension: Relation with the development of hypertensive end-stage renal disease. Am J Hypertens. 2005;18(11):1442–8.




DOI: https://doi.org/10.34117/bjdv.v7i5.29329

Refbacks

  • There are currently no refbacks.